Proton-pump inhibitors in patients requiring antiplatelet therapy: New FDA labeling

Postgraduate Medicine

Volumn 126, Issue 3, 2014, Pages 239-245

  Johnson, David A ^a   Chilton, Robert ^b   Liker, Harley R ^c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiplatelet therapy; Aspirin; Platelet aggregation inhibitors; Proton pump inhibitors

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DEXLANSOPRAZOLE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICAGRELOR; ACETYLSALICYLIC ACID; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; WOUND HEALING; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG LABELING; UNITED STATES;

ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; DRUG ANTAGONISM; DRUG LABELING; DRUG THERAPY, COMBINATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK FACTORS; TICLOPIDINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84906923063     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.05.2772     Document Type: Article

References (42)

1. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/ non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(7):645-681.
2. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-e425.
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
4. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533-2549.
5. ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360(20):2066-2078.
6. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: A cohort study. Ann Intern Med. 2010;152(6):337-345.
7. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102(3):507-515.
8. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363(20):1909-1917.
9. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115(6):813-818.
10. US Food and Drug Administration. FDA Announces New Warning on Plavix: Avoid Use with Prilosec/Prilosec OTC. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2009/ucm191169.htm. Accessed November 22, 2013.
11. Plavix (clopidogrel bisulfate). Full prescribing information. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2011.
12. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352(3):238-244.
13. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol. 2006;4(7):860-865.
14. Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol. 1998;275(3 pt 2):H1054-H1061.
15. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA. 2001; 98(11):6470-6475.
16. van Hecken A, Depre M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14(3):193-205.
17. Catalina Health. Catalina Health Rx Patient Panel. January 1-March 31, 2012.
18. Dexilant (dexlansoprazole). Full prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2012.
19. Nexium (esomeprazole magnesium). Full prescribing information. Wilmington, DE: AstraZeneca LP; 2012.
20. Prevacid (lansoprazole). Full prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2012.
21. Prilosec (omeprazole). Full prescribing information. Wilmington, DE: AstraZeneca LP; 2012.
22. Protonix (pantoprazole sodium). Full prescribing information. Konstanz, Germany: Nycomed GmbH; 2012.
23. Aciphex (rabeprazole sodium). Full prescribing information. Woodcliff Lake, NJ: Eisai Inc.; 2013.
24. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553-2560.
25. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
26. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
27. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997.
28. Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-1311.
29. Déry JP. SPICE: a prospective, randomized trial of four antacid strategies in patients receiving clopidogrel. Presented at the Transcatheter Cardiovascular Therapeutics conference; November 9, 2011; San Francisco, CA.
30. Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: Clinician update. Circulation. 2012;125(2):375-380.
31. Depta JP, Bhatt DL. Antiplatelet therapy and proton pump inhibition: Cause for concern? Curr Opin Cardiol. 2012;27(6):642-650.
32. Kwok CS, Loke YK. Meta-analysis: The effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810-823.
33. Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624-2641.
34. Andersson T, Nagy P, Niazi M, Nylander S, Wallentin L. Impact of omeprazole (OME), esomeprazole (ESO) o///acetylsalicylic acid (ASA) and lansoprazole (LAN) on the pharmacodynamics (PD) and pharmacokinetics (PK) of clopidogrel in healthy volunteers. Eur Heart J. 2012;33(abstr suppl):343.
35. Parri MS, Gianetti J, Dushpanova A, et al. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: Results of a pilot randomized trial. Int J Cardiol. 2013;167(5):2177-2181.
36. Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138(1):82-88.
37. Effient (prasugrel). Full prescribing information. Indianapolis, IN: Eli Lilly and Company; 2012.
38. Brilinta (ticagrelor). Full prescribing information. Wilmington, DE: AstraZeneca LP; 2011.
39. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028-2033.
40. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet. 2010;375(9711):283-293.
41. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74.
42. Paris B, Yerino P, Ogilvie B, Parkinson A. The proton pump inhibitors (PPIs) omeprazole and rabeprazole but not lansoprazole and pantoprazole are in vitro time-dependent inhibitors of CYP2C19. Drug Metab Rev. 2008;40:89-90.